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Abstract 
Malignant hyperthermia is a potentially fatal hypermetabolic disorder triggered by halogenated 
anesthetics and the myorelaxant succinylcholine in genetically predisposed individuals. 
Approximately 50% of Malignant Hyperthermia susceptible individuals carry dominant, gain of 
function mutations in RYR1 (which encodes ryanodine receptor type 1), though they have normal 
muscle function and no overt clinical symptoms. RyR1 is predominantly expressed in skeletal 
muscle but also to a lower extent in some immune and smooth muscle cells, suggesting that RYR1 
mutations may have a wider range of effects than previously suspected. Consistently, reports 
describing mild bleeding abnormalities in patients with malignant hyperthermia carrying gain of 
function RYR1 mutations have appeared. In the present report we sought to determine the 
	   3	  
frequency and molecular basis for this symptom. We found that some patients with specific RYR1 
mutations had abnormally high bleeding scores, whereas their healthy relatives did not. Knock-in 
mice with the Malignant Hyperthermia Susceptibility RYR1 mutation Y522S (MHS RYR1Y522S) 
had bleeding times that were 3 times longer than their wild-type littermates. Primary vascular 
smooth muscle cells from RYR1Y522S knock-in mice exhibited a higher frequency of 
subplasmalemmal Ca2+ sparks leading to a more negative resting membrane potential. The 
bleeding defect of RYR1Y522S mice and of one patient was reversed by treatment with the RYR1 
antagonist dantrolene, and Ca2+ sparks in primary vascular smooth muscle cells from the MHS 
RYR1Y522S mice were blocked by ryanodine or dantrolene. Thus, RYR1 mutations may lead to 
prolonged bleeding by altering vascular smooth muscle cell function. The reversibility of the 
bleeding phenotype emphasizes the potential therapeutic value of dantrolene in the treatment of 
such bleeding disorders. 
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Introduction 
Hemostasis is a stepwise process that causes bleeding to stop and can be grossly divided 
into primary and secondary hemostasis and three distinct stages. Primary hemostasis comprises 
(i) an instant vascular response to injury, leading to transient vasoconstriction limiting immediate 
blood loss, and (ii) platelet activation and aggregation, prompted by plasma Von Willebrand 
factor and sustained through platelet granule release that also enhances the initial 
vasoconstriction. Primary hemostasis results in formation of a platelet plug aimed at provisionally 
stopping the bleeding. Secondary hemostasis involves (iii) the sequential activation of clotting 
factors present in the plasma in an inactive state through a cascade of reactions, ultimately 
leading to the formation of a fiber-like mesh called fibrin that surrounds the provisional platelet 
plug and causes definite blood coagulation (1).   
Bleeding disorders are clinically and genetically heterogeneous and may affect all aspects 
of hemostasis. The most common causes are partial deficiencies of coagulation factors and 
fibrinolytic proteins, deficiencies in von Willebrand factor and platelet or connective tissue 
disorders (1). Nevertheless mild bleeding disorders are common in the general population but 
their precise incidence as well as their genetic background often remain unresolved (2,3). 
Mutations in RYR1, the gene encoding the skeletal muscle Ca2+ channel ryanodine 
receptor 1 (RyR1), have a calculated frequency of 1:2000-1:3000 (4). Dominant RYR1 mutations 
are commonly associated with Malignant Hyperthermia (MH), a severe pharmacogenetic reaction 
to halogenated anesthetics and muscle relaxants; exertional rhabdomyolysis/myalgia (ERM) (5) 
and the congenital myopathy Central Core Disease (CCD). Recessive RYR1 mutations have been 
associated with the congenital myopathies Multi-minicore Disease (MmD), Centronuclear 
Myopathy (CNM) and Congenital Fiber Type Disproportion (CFTD) (6-8). Bleeding 
abnormalities have been reported in isolated patients with MH Susceptibility (MHS) (9-11) and 
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homozygous mouse embryos knocked in for the Malignant Hyperthermia Susceptibility RYR1 
mutation Y522S (RYR1Y522S) display massive edema and subcutaneous blood effusions at birth, 
suggestive of a severe bleeding disorder with antenatal onset (12).  
Vascular smooth muscle cells play an important role in primary hemostasis and changes 
in the intracellular Ca2+ concentrations play a central mechanism regulating their relaxation and 
contraction (13). In addition to InsP3Rs, smooth muscle cells also express the three different RyR 
isoforms (13-17), and their Ca2+ homeostasis is more elaborate compared to many other excitable 
cell types. While InsP3R act as channels releasing Ca2+ from the endo(sarco)plasmic reticulum 
leading to smooth muscle cell contraction, the specific role of RyRs is more complex, and in 
contrast to striated muscle, RyRs are involved in smooth muscle cell relaxation (13,18,19). We 
hypothesized that there may be a correlation between the presence of dominant, Malignant 
Hyperthermia-related RYR1 mutations and mild bleeding abnormalities. 
In the present study we investigated the potential relationship between a mild bleeding 
disorder and the presence of dominant, gain of function RYR1 mutations; we then used the 
heterozygous RYR1Y522S mouse model to study the mechanism linking prolonged bleeding time 
to Ca2+ homeostasis in isolated smooth muscle cells. Our results indicated that gain-of-function 
RYR1 mutations mainly affected Ca2+ homeostasis of smooth muscle cells by increasing “Spark” 
(spontaneous calcium release events) activity. We also demonstrated that administration of the 
specific RyR1 antagonist dantrolene, which is clinically approved for the treatment of Malignant 
Hyperthermia reactions (20-21), reversed the bleeding phenotype by decreasing spark activity in 
vascular smooth muscle cells. 
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Results 
Human subjects carrying RYR1 mutations have a mild bleeding abnormality 
To investigate bleeding in RYR1-associated myopathies, we invited RYR1-mutated 
individuals and their non-mutated relatives to complete a standardized questionnaire ((Molecular 
and Clinical Markers for the Diagnosis and Management of Type 1 Von Willebrand’s Disease 
also known as MCMDM-1VWD)) validated for the evaluation of bleeding disorders (Table 1). 
Patients had neuromuscular features of Malignant Hyperthermia, ERM, a congenital myopathy 
(Central Core Disease or Multiminicore Disease) or a combination of these features, associated 
mainly with dominant heterozygous RYR1 missense mutations. A proportion of patients were 
compound heterozygous for 2 allelic RYR1 mutations, reflecting that some RYR1 mutations can 
be dominant with regards to Malignant Hyperthermia, but be recessives with regards to the 
congenital myopathy phenotype. The neuromuscular features of patients from families 1, 2, 4, 6, 
7, 8 and of their relatives have been previously reported. (5,22-24). MCMDM-1VWD bleeding 
questionnaires were obtained from 24 RYR1-mutated patients (12 females, 12 males) and 14 
relatives without the familial RYR1 mutation (4 females, 10 males). Symptoms of abnormal 
bleeding were common in RYR1-mutated individuals, characterized by severe menorrhagia and 
postpartum hemorrhage in females and milder symptoms of epistaxis and easy bruising in males. 
One male patient reported spontaneous hematomas in association with muscle cramps, while one 
female patient reported an additional history of recurrent and unexplained miscarriages. 
Improvement of menorrhagia was reported in one female (Patient 4.2) after prescription of 
sodium dantrolene, the specific RyR1 antagonist used clinically to reverse acute Malignant 
Hyperthermia reactions (20,21), for her severe ERM. Baseline hematological studies including 
evaluation of clotting factors and platelet aggregation studies were normal in all patients with 
symptoms of increased bleeding, except in patients 2.6 and 2.7 in whom abnormal von 
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Willebrand factor (vWF) levels were found, and patient 5.1 who had evidence of abnormal 
platelet function; bleeding scores from these patients were excluded from further statistical 
analysis as an alternative hematological diagnosis could not be confidently ruled out. Eight out of 
twenty-one (38%) patients included in the statistical analysis had a pathological bleeding score 
(≥4) on the questionnaire compared to 0/14 (0%) of controls (P=0.0118, Fisher exact testing with 
2-tailed P value). The mean bleeding score for patients is shown in Figure 1A. 	  
 
A mouse model knocked in for a human RYR1 mutation associated with Malignant 
Hyperthermia Susceptibility shows prolonged bleeding times. 
To gain mechanistic insight linking RYR1 mutations to bleeding, we used the 
heterozygous RYR1Y522S Malignant Hyperthermia Susceptible mouse (12). Applying a 
standardized test to accurately determine bleeding times in mice (25), we demonstrate that 
bleeding times in RYR1Y522S mice are 2-3 longer than in their wild-type littermates (Figure 1B 
for bleeding times in male mice and Supplementary Figure 1 for bleeding times in female mice). 
Intraperitoneal dantrolene administration to wild-type mice prior to the bleeding test did not 
affect bleeding times. However, pre-treatment of RYR1Y522S mice with dantrolene, but not with 
vehicle alone, reduced bleeding to the same times as those seen in their wild-type littermates 
(Figure 1B).  
Bleeding times depend on the contraction of injured blood vessels, platelet number and 
function, and the activation of circulating clotting factors. We have previously not found a 
difference in the number and function of circulating platelets between wild-type and RYR1Y522S 
mice (26). RyR1 is not detectable in platelets, virtually excluding disturbed platelet function as a 
potential cause for the bleeding disorder. Since wild-type and RYR1Y522S knock-in littermates 
only differ in their RYR1, we hypothesized that these differences in bleeding times could be due 
	   8	  
to changes in the contraction and relaxation properties of the smooth muscle cells lining the blood 
vessels. Vessel reactivity can be assessed using a vessel injury model however because of their 
small size (with a diameter of 0.26±0.03 mm) we could not accurately measure changes in the 
diameter of the tail artery, which would be a direct indication of contraction/relaxation. 
Furthermore, because of their predisposition to malignant hyperthermia deep anaesthesia was not 
possible in the RYR1Y522S knock-in mice, excluding the possibility of performing injury 
experiments in larger blood vessels. The fact that direct measurements could not be performed 
constitutes a limitation to our study, however in order to demonstrate a cause –effect relationship 
between RYR1 mutations and vessel response, we used the Pulsed-Wave Doppler and measured 
velocity of blood flow (27,28), at a point 1 cm upstream from the incision of the tail artery, at a 
constant blood pressure (Supplementary Figure 2). Velocity of blood is inversely related to vessel 
diameter (29) and therefore changes in velocity reflect changes in the contraction and relaxation 
status of smooth muscle cells. Under baseline conditions, there were no differences in blood flow 
velocity through the caudal artery between WT and RYR1Y522S mice (Figure 1C). However, in 
response to injury and more specifically at 8-10 minutes post incision, the velocity of blood flow 
in the tail artery of WT mice was significantly faster than in that of RYR1Y522S mice. This result 
indirectly indicates that vasoconstriction occurs to a larger extent in the tail arteries of WT than in 
RYR1Y522S mice. 
qPCR experiments confirmed the expression of RYR1 in primary arterial vascular smooth 
muscle cells, which was normalized to DES, which encodes desmin, a skeletal and smooth 
muscle cell-specific protein (30). Cells in mouse aorta and tail artery express the RYR1 transcript, 
though as expected, to a much lower extent than skeletal muscle (Figure 2A) and the presence of 
the RYR1Y522S mutation in the heterozygous state does not affect the expression of RYR1 (Figure 
2B) no of RYR2 and RYR3 (Supplementary Figure 3). RT-PCR on mRNA isolated from tail 
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arteries confirmed the expression of a mutated transcript in the heterozygous RYR1Y522S mice 
(Figure 2C). Confocal immunohistochemical analysis on isolated primary vascular smooth 
muscle cells confirmed the presence of the specific smooth muscle marker actin (Fig. 2D, central 
panels). Analysis of the subcellular distribution of RyR1 using an antibody that under our 
experimental conditions does not cross react with RyR2 (Supplementary figure 4) showed that 
RyR1s are localized close to the plasma membrane (Figure 2E, red). This distribution is similar to 
that of the voltage sensing dihydropyridine receptor Cav1.2 which is found on the plasma 
membrane of vascular smooth muscle cells (figure 2E, green) (31-33). The subcellular 
distribution of RyR1 in isolated primary vascular smooth muscle cells is similar to that reported 
in pulmonary artery smooth muscle cells and in vas deferens (33-35); in the latter cells, localized 
RyR1-mediated calcium release from subplasmalemmal stores causes activation of BK channels 
resulting in cellular hyperpolarization leading to vasodilation (35, 36).  
 
Calcium homeostasis in vascular smooth muscle cells isolated from the RYR1Y522S mouse is 
significantly different compared to that of their wild-type littermates 
To investigate how RYR1 mutations affect Ca2+ homeostasis, we isolated primary vascular 
smooth muscle cells from mouse-tail arteries. We used this cellular model since bleeding times 
have been assessed on this tissue and these cells are responsible for the control of the vasomotor 
activity in the tail (37). The resting Ca2+ concentration was similar in primary vascular smooth 
muscle cells isolated from wild-type and RYR1Y522S mice (Fig.3 A and B), though the latter cells 
showed significantly smaller total rapidly releasable Ca2+ stores compared to those isolated from 
wild-type littermates  (Fig.3C). In smooth muscle cells, local calcium release events termed “Ca2+ 
sparks” have been ascribed to the opening of single or clusters of RyR channels. Although they 
have little or no direct effect on contraction, they indirectly lead to vasodilation through 
	   10	  
activation of BK channels (13,18). We studied spark activity in isolated primary vascular smooth 
muscle cells isolated from tail arteries loaded with the fast calcium dye Fluo-4 (Fig. 3D). The 
frequency of sparks (sparks/image) is given in Figure 3 E and representative videos of sparks 
occurring in cells from wild-type and RYR1Y522S mice are shown in Supplementary Videos 1 and 
2, respectively. Detailed analysis of spark amplitude and kinetics revealed small but significant 
differences between cells isolated from WT and RYR1Y522S knock in mice (Supplementary Table 
1) .  
We next used several drugs including RyR1 blockers and the InsP3R antagonist 
Xestospongin C to determine the origin of these spontaneous Ca2+ release event. Sparks were 
extinguished in wild-type and RYR1Y522S primary vascular smooth muscle cells by pre-
incubation with Ryanodine (Figure 3E and Supplementary Video 3). Additionally, pre-incubation 
with dantrolene significantly decreased spark frequency in both wild-type and RYR1Y522S cells 
(Figure 3 E and Supplementary Video 4). This effect was not observed when cells were incubated 
with the InsP3 antagonist Xestospongin C (Supplementary Video 5). These results indicated that 
RyR1 was present in primary vascular smooth muscle cells, that RYR1 mutations leading to MHS 
were not only present in skeletal muscle but also in arterial smooth muscle cells, and that the 
RYR1Y522S mutation increased the frequency of spark events. In skeletal muscle, RYR1 mutations 
associated with MHS are gain-of-function mutations leading to an increased sensitivity to 
activating stimuli, resulting in prolonged and sustained muscle contractions (38-41). Our results 
suggested that a similar mechanism did not operate in smooth muscle cells since RYR1 mutations 
caused prolonged rather than shorter bleeding times, which would be expected if mutated RyR1 
caused a gain of function in primary vascular smooth muscle cells. In skeletal muscle, excitation-
contraction coupling depends on the mechanical interaction between the voltage sensing 
dihydropyridine receptor and the RyR1 (42), whereas in smooth muscle cells the functional unit 
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is made up of dihydropyridine receptors, ryanodine receptors and BKCa channels (13,18).  RyR 
dependent Ca2+ sparks activate BKCa channels causing plasma membrane hyperpolarization 
thereby decreasing Ca2+ influx through the dihydropyridine receptor and leading to smooth 
muscle relaxation (13,18). We found that vascular smooth muscle cells from RYR1Y522S mice 
were significantly more hyperpolarized than those from wild-type mice, which had membrane 
potentials in line with previous reports (18) (Figure 4A). Furthermore, the membrane potential of 
cells from the RYR1Y522S mice was reverted to control values after treatment with dantrolene 
(Figure 4A).  
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Discussion 
In the present study we demonstrate that gain-of-function RYR1 mutations associated with 
MH and/or exertional rhabdomyolysis cause a mild but distinct bleeding disorder in humans and 
a corresponding phenotype in a murine model of Malignant Hyperthermia, by affecting vascular 
smooth muscle cell calcium homeostasis. A model showing how RYR1 mutations affect smooth 
muscle cell contraction is shown in Figure 4B. Characteristic features of the human bleeding 
phenotype were female preponderance, presentation with marked menorrhagia, postpartum 
bleeding and a history of miscarriages in the context of normal coagulation tests. Although in our 
study we evaluated a relatively small sample of RYR1-mutated patients and controls, the clinical 
data are consistent with the data obtained from the corresponding mouse model carrying the 
murine equivalent of a human Malignant Hyperthermia-related RYR1 mutation (12). The large 
variation in the bleeding times of RYR1Y522S mice may reflect different extents of contraction of 
the skeletal muscles within the mouse tail when placed at 37°C. Alternatively it may be due to 
intrinsic structural properties of the RyR complex, which in smooth muscle cells obtained from 
the tails of RyR1Y522S mice has a protomeric composition. A variation in the proportion of 
protomers encoded by wild-type and mutated alleles within the tetrameric RyR1 Ca2+ channel 
complex affects the biophysical properties of the RyR1 complex (43) and therefore may account 
for the variability of the calcium signals responsible for vascular responses. This explanation is in 
agreement with the data obtained from wild-type mice, which exhibit much more consistent 
bleeding times, presumably because of the homogeneous protomeric composition within the 
RyR1 tetrameric protein complex. Our mouse data is also consistent with our findings from 
humans, in that higher mean bleeding scores correlated with greater variability in RYR1-mutated 
patients compared to relatives without the familial RYR1 mutation.  Prolonged bleeding times in 
the RYR1Y522S mice and in one patient were reversed by administration of the specific RyR1 
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antagonist dantrolene, supporting an association between the observed bleeding phenotype and 
the RYR1 mutant state.  These results suggest that dantrolene could be administered as a 
pharmacological treatment for RYR1-related bleeding disorders and, potentially, other causes of 
prolonged bleeding due to impaired vascular smooth muscle cell contractility rather than primary 
platelet or coagulation factor abnormalities. Considering that carriers of Malignant Hyperthermia 
-associated RYR1 mutations are frequent (1:2000-1:3000)(4) but often asymptomatic unless 
exposed to triggering agents, such mutations may account for common mild bleeding 
abnormalities in humans that are currently without genetic explanation. Of note, we found 
evidence of abnormal platelet function and borderline reduced vWF levels in 1 and 2 RYR1-
mutated patients within our cohort, respectively. These patients were not considered for the final 
statistical analysis as we could not exclude a primary platelet or vWF abnormality as an 
alternative explanation for the observed bleeding phenotype. However, similar findings of mildly 
abnormal platelet function and vWF levels have been reported in other non-hematological 
disorders associated with prolonged bleeding such as collagen disorders (44) or Noonan 
syndrome (45), where the primary defect does not concern platelets or coagulation factors and 
may therefore well be a secondary feature also in the RYR1-related bleeding disorder reported in 
this study.     
Our observations are consistent with emerging knowledge concerning the dynamic and 
complex role of BKCa channels and RyR in tissue-specific vasoregulation: Pressure-induced RyR 
activation in mesenteric resistance arteries has a strong vasodilatory effect, mediated by Ca2+–
induced activation of BKCa channels and, possibly, Ca2+–induced inactivation of L-type voltage-
dependent Ca2+ channels (VDCCs) (46). Considering that RyR2 rather than RyR1 is the 
predominant RyR isoform in murine mesenteric arteries (47), the RYR1-associated arterial 
smooth muscle cell phenotype seems unexpected. However, in this context distinct spatial 
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distribution may be more important than relative amount of RyR isoforms. As we have 
demonstrated in murine arterial smooth muscle cells, RyR1s are predominantly found 
subsarcolemmally, and altered activity of the mutant RyR1s may be more consequential because 
of their close proximity to BKCa channels. We also cannot exclude the possibility that the release 
of Ca2+ from mutated RyR1 channels may facilitate the opening of adjacent RyR2 channels 
through the regenerative Ca2+ induced Ca2+ release mechanism (48).  
Our study reports a non-neuromuscular phenotype, that is abnormal bleeding, in RYR1-
related myopathies and is likely to inform the surveillance and anticipatory management of 
patients affected by these conditions. Considering that RyR1 is found in many types of tissues, 
non-neuromuscular manifestations of RYR1 mutations are not unexpected but may have been 
overlooked, because they are mild and/or involve symptoms that are not necessarily considered 
part of a neuromuscular disorder. The marked female preponderance in our series with severe 
menorrhagia and/or post-partum hemorrhage raises the question of more extensive smooth 
muscle cell involvement in RYR1-related myopathies. Such additional smooth muscle cell 
involvement may confound the observed bleeding phenotype, in a gender-specific manner in 
particular on the uterine level, considering that smooth muscle cells also play an important role in 
uterine vasoregulation and myometrial contraction (49,50). Indeed, patients from two of our 
families reported prominent bowel and bladder involvement (urinary incontinence, vesicoureteral 
reflux, “spastic colon”), suggesting more widespread smooth muscle cell involvement also in 
keeping with a role of both RyRs and BKCa channels in bladder smooth muscle signaling (51). 
Although beyond the goal of the present study to specifically investigate bleeding abnormalities 
in patients with RYR1 mutations, these observations should prompt future investigations into the 
association between RYR1 mutations and a more generalized smooth muscle dysfunction both on 
the clinical and cellular level.              
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Materials and Methods 
Patients: Patients were identified through the participating tertiary neuromuscular and malignant 
hyperthermia (MH) centers. Genetic testing and haematological studies including evaluation of 
clotting factors and platelet aggregation were performed as part of the routine diagnostic workup. 
Patients were invited to complete the MCMDM-1VWD (= Molecular and Clinical Markers for 
the Diagnosis and Management of Type 1 Von Willebrand’s Disease) bleeding questionnaire, a 
validated and widely used diagnostic tool in the evaluation of bleeding disorders (52). 
MCMDM1-VWD bleeding questionnaires were scored independently by two clinicians blinded 
to the genetic status (mutated or non-mutated) of the proband. The study received UK Research 
Ethics Committee approval (15/WS/204, granted by the West of Scotland REC 5). Patients gave 
informed consent for anonymized publication of their clinical information. 
Animal Model: Experiments were carried out on 7-12 week old heterozygous RYR1Y522S knock-
in mice and their wild type littermates. The mouse model was generated by Chelu et al. (12) and 
was a generous gift of Dr. Susan Hamilton, Baylor College of Medicine, Houston, Texas USA. 
Experimental procedures were approved by the Veterinary Cantonal Authorities (Permit numbers 
1728 and 1729).  
Bleeding time assay: Bleeding time was determined according to Liu et al. (25). Intraperitoneal 
injections with dantrolene (10 mg/kg) or vehicle alone (saline solution) were administered 1 h 
prior to bleeding time determination. 
Pulsed-wave Doppler: Male mice (15-20 weeks old) were lightly anaesthetized with 
Ketamine/Xylazine (95mg/Kg Ketamine +10 mg/kg Xylazine) and placed on a heated blanket at 
26 °C. Blood flow velocity in the tail artery was measured using a Pulse-Wave Doppler 
ultrasound system (Vevo 2100, VisualSonics Inc., Toronto, Canada) at high frequency (32 MHz, 
MS 550D transducer). The probe was positioned where a consistent signal could be detected at 
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the proximal end of the tail, approximately 1 cm from the base of the tail. Velocity of blood flow 
was measured before and at 6 time points after an incision was made on the tail artery; 
measurements were made 1 cm upstream from the incision site. The velocity was measured 
during 5 consecutive cardiac cycles and the mean blood flow velocity per mouse was plotted at 
each time point before and after incision. The experimenters were blinded and had no prior 
knowledge of the genotype of the mice. Data were analyzed and plotted using the GraphPad 
Prism V 6.0 and Origin Pro 8.6.0 softwares. 
Blood pressure measurements: Systolic blood pressure was monitored in conscious mice using a 
non-invasive tail-cuff photoplethysmography sytstem (BP-2000 Blood Pressure Analysis System, 
Visitech Systems). Blood pressures were assessed in a quiet environment at the same time of day, 
for a period of 7 days prior to the actual measurements, in order to allow the mice to adjust to the 
protocol. Each symbol represents the blood pressure value of individual mice. 
Isolation of single smooth muscle cells: Primary vascular smooth muscle cells were isolated 
essentially as described (53) using an enzymatic cocktail containing 9.6 U/ml papain (Sigma # 
P4762), 1200U/ml collagenase (Worthington # LS004176), 2.58U/ml elastase (Worthington # 
LS002292), 0.6% bovine serum albumin (BSA) and 1 mg/ml soybean trypsin inhibitor 
(Worthington # LS003587).  
Calcium imaging and Spark analysis: The resting calcium fluorescence was measured using the 
calcium indicator fura-2 AM (Invitrogen) (26) and the total amount of Ca2+ present in the rapidly 
releasable intracellular stores was determined as previously described (54). Calcium sparks were 
measured in cells loaded with 5 µM Fluo-4 using a Nikon A1R laser scanning confocal 
microscope (Nikon Instruments Inc. Melville, USA) with a 60× oil immersion Plan Apo VC 
Nikon objective (NA 1.4). Five sec duration linescan images (x,t) were acquired in resonant mode 
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at super high temporal resolution (7680 lps) with 512 pixels (0.05 µm/pixel) in the x- and 39936 
pixels (0.126 ms/pixel) in the t-direction using a pinhole size of 72.27 µm. Four to five images 
were taken at different positions across each cell. Fluo-4 was excited with a laser at 487 nm and 
the fluorescence emitted at 525+/-25 nm was recorded. Images were analysed using the open 
source image processor software Fiji (55). After binning 4X in the temporal axes, linescan images 
were run with the automated sparks processor plugin SparkMaster (56).  
Immunofluorescence: Cells were fixed with ice-cold methanol: acetone (1:1) for 30 min and 
processed as previously described (54). The primary antibodies used were: mouse anti-smooth 
muscle actin (Sigma #A5228), mouse anti-RyR1 (Thermo Scientific #MA3-925), rabbit anti-
Cav1.2 (Santa Cruz # sc-25686) and the secondary conjugates were anti-mouse Alexa Fluor 568 
and chicken anti-rabbit Alexa Fluor 488 (Lubio science). Nuclei were counterstained with DAPI 
(25-30 µM) for 5 min prior to mounting. Cells were examined by confocal microscopy using a 
Nikon A1R laser scanning confocal microscope with a 60× oil immersion Plan Apo objective. 
 Real Time qPCR and RT PCR: Total RNA was extracted and treated with deoxyribonuclease I 
(Invitrogen) as previously described (26). After reverse transcription using 1000-1500 ng of 
RNA, cDNA was amplified by quantitative real-time PCR with a 7500 Fast Real-Time PCR 
system (Applied Biosystems) using SYBR Green technology (fast SYBR green master mix, 
Applied Biosystems) and the following primers: RYR1 F: 5’-TCA CTC ACA ATG GAA AGC 
AG-3’; R: 5’-AGC AGA ATG ACG ATA ACG AA-3’; DES F: 5’-TGA GAC CAT CGC GGC 
TAA GA-3’ and R: 5’-GTG TCG GTA TTC CAT CAT CTC C-3’. Gene expression was 
normalized to desmin (DES) content as this marker is specifically expressed in muscle cells (30, 
57). RYR1 expression levels in mouse aorta, tail artery and mesenteric artery were compared to 
RYR1 expression levels in Extensor Digitorum Longus (EDL), that latter being the reference 
tissue set to 1. RYR1 expression in aorta was also investigated by semi-quantitative RT PCR as 
	   18	  
previously described (26).  
Membrane potential measurements: Membrane potential measurements were performed using 
the potentiometric fluorescence dye Bis-Oxonol as described (58). Briefly, isolated arterial 
smooth muscle cells were plated on laminin: gelatin (1:10 ratio) pre-coated coverslips and 
allowed to attach for 20 min in a modified Krebs-Ringer solution (in mM: NaCl: 140; CaCl2: 0.5; 
KCl: 5; MgSO4: 1; HEPES: 10; Na2HPO4: 1; Glucose: 5.5 and Albumin 1%). Cells were loaded 
with the potentiometric fluorescence dye Bis-Oxonol (Molecular Probes, B438) in the presence or 
absence of 20 µM dantrolene at room temperature for 30-40 min. To calibrate the membrane 
potential cells were incubated with the Na+ ionophore gramicidin (10 µM) (Sigma, G 5002) and 
then exposed to different Na+ containing solutions (Supplementary Figure 5). The concentration 
ratios of Na+ and Choline were varied in order to maintain [Na+] + [Choline] = 144 mM. 
Theoretical values for membrane potential were calculated according to the formula: Em = 60 
Log([Na+]o + [K+]o)/( [Na+]i + [K+]i), and considering the internal concentration of Na+ and K+ as 
described by Nelson et al. (18). Fluorescence was recorded every 0.5 min with a Nikon A1 plus 
confocal microscope, using a 60X oil objective. Samples were illuminated with a Sapphire Laser 
at 488 nm and the fluorescence emitted at 525/50 nm was recorder. Fluorescence images were 
processed using the open source software Fiji.  
Statistical analysis and graphical software: Statistical analysis on the MCMDM1-VWD 
bleeding questionnaires was performed by converting raw bleeding scores to binary numbers for 
use in Fisher exact testing with 2-tailed p value (negative screening test ≤3, positive screening 
test ≥4). Mean scores were compared using Student’s t test. For all other experiments statistical 
analysis was performed using the Student's t test; means were considered statistically significant 
when the P value was <0.05. Data was processed, analysed and plotted using the software 
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OriginPro 8.6.0 (OriginLab Corporation). Images were assembled using Adobe Photoshop CS 
(version 8.0). 
Supplementary Information 
Supplementary Figure 1: RYR1Y522S female mice also exhibit prolonged bleeding times  
Supplementary Figure 2: Heart rate and systolic blood pressure are similar in WT and 
RYR1Y522S mice. 
 Supplementary Figure 3: Expression of RYR2 and RYR3 are not significantly different in the 
tail arteries of WT and RYR1Y522S mice.  
Supplementary Figure 4: Specificity of the anti-RyR1 antibodies used for IHC.  
Supplementary Figure 5:	  Membrane potential measurements using the fluorescence 
potentiometric probe Bis-Oxonol. 
Supplementary Table 1: Detailed analysis of full kinetic parameters of sparks in vascular 
smooth muscle cells from WT and RYR1Y522S mice. 
Supplementary Video 1:  Sparks in smooth muscle cells from WT mice.  
Supplementary Video 2:  Sparks in smooth muscle cells from RYR1Y522S mice.  
Supplementary Video 3:  Sparks in smooth muscle cells from WT mice after treatment with 10 
µM ryanodine. 
Supplementary Video 4:  Sparks in smooth muscle cells from RYR1Y522S mice after treatment 
with 20 µM dantrolene.  
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Supplementary Video 5: Sparks in smooth muscle cells from RYR1Y522S mice after treatment 
with 250 nM Xestospongin C.   
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Figure Legends 
Figure 1. RYR1 mutations are associated with prolonged bleeding times. A. 
Scatterplot of MCMDM-1VWD bleeding scores for RYR1-mutated patients compared to related 
controls without the familial RYR1 mutation(s) (mean score 2.3 in cases compared to -0.4 in 
controls, P<0.005, Student’s t-test). Eight out of thirteen female patients had abnormal bleeding 
scores compare to 0/4 female controls (P<0.03, Student’s t-test). The mean bleeding score for 
female patients was 4.5 (range 2 to 9), and -1.3 (range -2 to 0) in controls (P<0.0005, Student’s t-
test).	  B. RYR1Y522S knock in MHS mice showed prolonged bleeding times that were reversed by 
dantrolene. Each symbol represents the bleeding time (in sec) of a single WT (light grey) and 
RYR1Y522S (dark grey) mouse. Mice were either untreated, pre-treated with dantrolene or pre-
treated with vehicle alone. **P<0.05 Students t-test. C. Blood flow velocity in the caudal artery 
before and after incision. Each symbol represents the mean of 5 measurements performed on each 
mouse at the indicated time. Light grey symbols, WT mice; dark grey symbols, RYR1Y522S mice. 
*P<0.004 and *** P<0.0001 Student’s t test.	  
Figure 2. RyR1 is present at the mRNA and protein level in aortae and tail arteries and is 
localized close to the plasma membrane. A. RYR1 expression in skeletal muscle (SKM), aorta, 
tail (TA) and mesenteric artery (MA) was normalized to DES content, which is present in skeletal 
and smooth muscle cells (30). The numbers below the bars indicate number of mice used for the 
analysis. B. The presence of the Y522S mutation does not affect RYR1 expression as determined 
by qPCR. The numbers below the bars indicate number of mice used for the analysis. C. Total 
RNA was extracted from purified aortas and the expression of RYR1 was evaluated by RT-PCR. 
Digestion of the amplified RYR1 cDNA from WT mice yielded the uncut band of about 376 bp.  
Digestion of the cDNA from heterozygous RYR1Y522S mice yielded two bands of 276 bp and 100 
bp plus the uncut 376 bp band from the WT allele. Image is representative of 2 independent 
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experiments with 2 mice analyzed per genotype. D. Phase contrast of an isolated primary vascular 
smooth muscle cell (left); confocal immunofluorescence on the same cell using a mouse antibody 
specific for smooth muscle actin followed by anti–mouse Alexa Fluor 569 (middle) or DAPI to 
localize the nucleus (right). Images are representative of cells from 4 mice per genotype. E. Phase 
contrast on an isolated primary vascular smooth muscle cell (leftmost image). Confocal 
immunofluorescence of the same cell stained with mouse monoclonal anti-RyR1 mAb followed 
by anti-mouse Alexa Fluor-568 (red), rabbit anti-Cav1.2 followed by anti-rabbit Alexa Fluor-488 
(green), DAPI (blue). Composite image showing co-localization of RyR1 and Cav1.2 (rightmost 
image). Images are representative of cells from 4 mice per genotype. Scale bar = 10 µm. 
Figure 3. Arterial smooth muscle cells from RYR1Y522S mice exhibit smaller intracellular 
Ca2+ stores and a higher frequency of spontaneous Ca2+ sparks. A. Representative Fura-2 
traces of resting fluorescence ratios (340/380 nm) of primary vascular smooth muscle cells 
isolated from WT (light grey) and a RYR1Y522S (dark grey) mice. B Mean resting fluorescence 
ratios from primary vascular smooth muscle cells isolated from 2 WT (n=20 cells) and 2 
RYR1Y522S knock in (n=20 cells) mice. The values were not significantly different. C. Total 
amount of Ca2+ in the thapsigargin/ionomycin-sensitive stores was significantly lower in vascular 
smooth muscle cells from 2 RYR1Y522S mice (n=20 cells) compared to those from 2 WT (n=20 
cells) mice. *P< 0.05 Student’s t test. D. Top row (left) brightfield image and (right) fluo-4 
fluorescent photomicrograph of an isolated smooth muscle cell. Bar, 10 µm. Bottom, 
representative pseudocolour and greyscale linescan images of spontaneous localized calcium 
release events (sparks) in vascular smooth muscle cells. Experiments were performed on cells 
from WT (top) and RYR1Y522S (bottom) mice. The color scale indicates the fluorescence change 
calculated as the F/F0 ratio. The traces under the linescan images show the time course of the 
calcium sparks. Scale bars: vertical 10 µm, horizontal 100 ms, pseudocolor F/F0. E. Mean 
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(±SEM) spark frequency in vascular smooth muscle cells from 6 WT (light grey, n=28 cells) and 
6 RYR1Y522S (dark grey, n=28) mice. **P<0.03; ***P< 0.0001 Student’s t test when comparing 
cells ± dantrolene and ± ryanodine  
Figure 4: Smooth muscle cells from RYR1Y522S mice are more hyperpolarized than those 
from WT mice, and schematic representation of RyR1 function in arterial smooth muscle 
cells. A. The resting membrane potential was measured using the potentiometric probe Bis-
Oxonol in vascular smooth muscle cells from WT mice (7 controls, 2 + dantrolene)  and  
RYR1Y522S mice (4 controls and 2 +dantrolene ) (see also Supplementary Figure 5). n indicates 
the number of individual cells that were assessed. Cells were either left untreated (control) or 
pretreated with 20 µM dantrolene for 30 minutes.* Mean resting membrane potential was 
significantly different between WT and RYR1Y522S mice (Student’s t-test P<0.05). B. Schematic 
representation of the mechanism leading to prolonged bleeding time due to RYR1 mutations. In 
normal conditions (left panel), early vasospasm occurring immediately after injury reduces 
bleeding (in coordination with platelets and coagulation factors not shown here). Mutations in 
RYR1 (right panel) result in hyperpolarization of the smooth muscle cell membrane potential, 
reducing the ability of vessels to contract and ultimately increasing the bleeding time. PM: 
Plasma Membrane, SR: Sarcoplasmic Reticulum, RyR1: Ryanodine Receptor Type 1, BK: 
Calcium activated Potassium Channel. Blue balls: Potassium, peach balls: calcium sparks, WT: 
Wild Type, RyR1Y522S : MH knock-in. 
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Table 1. Genetic details, neuromuscular features, MCMDM-1VWD bleeding questionnaire 
scores, and bleeding phenotypes from patients with RYR1-related myopathies and their 
healthy relatives. 
F	  
P/
C	   S	   RYR1	  mutation(s)	   I	   NM	  
RYR1	  
+/-­‐	  
B
S	   Bleeding	  phenotype	  
	   	   	   	   	   	   	   	   	  
1	  
1.
1	   F	  
p.R2241X,	  p.D708N;	  
p.R2939K	  
A
R	  
MmD/
MH	   +	   5	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	   	   	   	   	   	   	   	   	  
	  
2.
1	   F	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   6	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	  
2.
2	   F	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   9	   Severe	  menorrhagia;	  Postpartum	  bleeding	  
	  
2.
3	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
2.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	   3	  
Rectal	  bleeding	  (diverticulitis	  ?);	  Bleeding	  
after	  dental	  extraction	  
2	  
2.
5	   M	   -­‐	   -­‐	   -­‐	   -­‐	   2	   Rectal	  bleeding	  (colitis	  ?)	  
	  
2.
6	   M	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   4	   Epistaxis;	  Easy	  bruising*	  
	  
2.
7	   M	   p.G4638D	  
A
D	  
CCD/M
HS	   +	   1	   Easy	  bruising*	  
	  
2.
8	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
2.
9	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
1	   not	  applicable	  
	  
2.
10	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
2.
11	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
1	   not	  applicable	  
	   	   	   	   	   	   	   	   	  
3	  
3.
1	   F	  
p.S1342G,	  p.A1352G,	  
p.T2787S	  
A
D	   ERM	   +	   2	   Menorrhagia;	  Epistaxis	  
	  
3.
2	   F	  
p.S1342G,	  p.A1352G,	  
p.T2787S	  
A
D	   ERM	   +	   2	   Menorrhagia;	  Oral	  cavity	  bleeding	  
	   	   	   	   	   	   	   	   	  
	  
4.
1	   F	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   7	   Severe	  menorrhagia;	  Epistaxis	  
	  
4.
2	   F	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   4	   Severe	  menorrhagia#	  
4	  
4.
3	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   Epistaxis	  
	  
4.
4	   F	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
4.
5	   M	   p.G2434R	  
A
D	  
ERM,	  
MHS	   +	   3	   Epistaxis;	  Bleeding	  after	  dental	  extraction	  
	   	   	   	   	   	   	   	   	  
5	  
5.
1	   F	   p.H3981Y	  
A
D	   ERM	   +	  
1
3	   Severe	  menorrhagia;	  	  Postpartum	  bleeding*	  
	  
5.
2	   M	  
p.T4288_A4290dup;	  
p.H3981Y	  	  
A
D	   ERM	   +	   2	   Muscle	  haematoma	  after	  muscle	  cramps	  
	   	   	   	   	   	   	   	   	  
	  
6. F	   p.T4288_A4290dup	   A ERM	   +	   4	   Menorrhagia;	  Postpartum	  bleeding	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1	   D	  
6	  
6.
2	   F	   p.T4288_A4290dup	  
A
D	   ERM	   +	   4	  
Easy	  bruising;	  Oral	  cavity	  bleeding;	  GI	  
bleeding	  
	  
6.
3	   M	   p.T4288_A4290dup	  
A
D	   ERM	   +	   1	   Bleeding	  from	  minor	  wounds	  
	   	   	   	   	   	   	   	   	  
	  
7.
1	   M	   p.V4849I	  
A
D	   ERM	   +	  
-­‐
2	   not	  applicable	  
7	  
7.
2	   M	   p.V4849I	  
A
D	   ERM	   +	  
-­‐
1	   not	  applicable	  
	  
7.
3	   M	   p.I2321V;	  p.V4849I	  
A
D	   ERM	   +	   0	   not	  applicable	  
	  
7.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
5	   F	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
6	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	  
7.
7	   M	   -­‐	   -­‐	   -­‐	   -­‐	   0	   not	  applicable	  
	   	   	   	   	   	   	   	   	  
	  
8.
1	   M	   p.R614C	  
A
D	   MHS	   +	   1	   Oral	  cavity	  bleeding	  
	  
8.
2	   M	   p.R2676W	  
A
D	   MHS	   +	  
-­‐
2	   not	  applicable	  
8	  
8.
3	   M	   p.R614C	  
A
D	   MHS	   +	  
-­‐
1	   not	  applicable	  
	  
8.
4	   M	   -­‐	   -­‐	   -­‐	   -­‐	  
-­‐
2	   not	  applicable	  
	  
8.
5	   F	   p.R2676W	  
A
D	   MHS	   +	   2	   Menorrhagia	  
	   	   	   	   	   	   	   	   	  
9	  
9.
1	   F	   p.R2454H	  
A
D	   MHS	   +	   4	  
Easy	  bruising;	  Postpartum	  bleeding;	  Muscle	  
hematoma	  
	  
9.
2	   M	   p.R2454H	  
A
D	   MHS	   +	  
-­‐
2	   not	  applicable	  
	  
	   	   	   	   	   	   	   	  
	  
Abnormal MCMDM-1VWD bleeding scores (>4) are highlighted in red. Patient 1.1 was 
deceased and the MCMDM-1VWD bleeding questionnaire was completed retrospectively 
based on information in the patient medical notes. *Three patients (2.6, 2.7, 5.1) were 
excluded from further statistical analysis because of abnormal von Willebrand factor levels 
(2.6, 2.7) and evidence of abnormal platelet function (5.1), respectively. #Patient 4.2 reported 
improvement of bleeding symptoms following commencement of dantrolene treatment, which 
was prescribed for exertional myalgia. Two dominant heterozygous MHS-related RYR1 
mutations were running independently in families 5, 7 and 8. RYR1-mutated individuals in 
families 2 and 5 reported additional symptoms suggestive of smooth muscle involvement 
concerning both bladder and bowel (urinary incontinence, vesicoureteral reflux, “spastic 
colon”). Neuromuscular features from families 1, 2, 4, 6, 7 and 8 have been previously 
reported. F = Family; P/C = Patient/Control; I = Inheritance; NM = Neuromuscular 
phenotype; RYR1 +/- = RYR1 mutation carrier state; BS = MCMDM-1VWD bleeding score; 
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CCD = Central Core Disease; MHS = Malignant Hyperthermia Susceptibility; ERM = 
exertional rhabdomyolysis.  
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Figure 1: 
 
Figure 2: 
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Figure 3: 
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